ES2180523T3 - Composicion que comprende insulina nph (insulina neutra protamina de hagedorn). - Google Patents

Composicion que comprende insulina nph (insulina neutra protamina de hagedorn).

Info

Publication number
ES2180523T3
ES2180523T3 ES01106315T ES01106315T ES2180523T3 ES 2180523 T3 ES2180523 T3 ES 2180523T3 ES 01106315 T ES01106315 T ES 01106315T ES 01106315 T ES01106315 T ES 01106315T ES 2180523 T3 ES2180523 T3 ES 2180523T3
Authority
ES
Spain
Prior art keywords
insulin
hagedorn
neutral
composition including
nph
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES01106315T
Other languages
English (en)
Inventor
Ross G Clark
James Q Oeswein
Douglas A Yeung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2180523T3 publication Critical patent/ES2180523T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composición que comprende insulina NPH (insulina neutra protamina de Hagedorn) en un tampón de sal de ácido acético sin la presencia de IGF-I.
ES01106315T 1996-08-13 1997-07-31 Composicion que comprende insulina nph (insulina neutra protamina de hagedorn). Expired - Lifetime ES2180523T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/696,314 US5783556A (en) 1996-08-13 1996-08-13 Formulated insulin-containing composition

Publications (1)

Publication Number Publication Date
ES2180523T3 true ES2180523T3 (es) 2003-02-16

Family

ID=24796556

Family Applications (2)

Application Number Title Priority Date Filing Date
ES97935259T Expired - Lifetime ES2162321T3 (es) 1996-08-13 1997-07-31 Composicion que comprende insulina y factor de crecimiento-i similar a la insulina (igf-i).
ES01106315T Expired - Lifetime ES2180523T3 (es) 1996-08-13 1997-07-31 Composicion que comprende insulina nph (insulina neutra protamina de hagedorn).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES97935259T Expired - Lifetime ES2162321T3 (es) 1996-08-13 1997-07-31 Composicion que comprende insulina y factor de crecimiento-i similar a la insulina (igf-i).

Country Status (16)

Country Link
US (1) US5783556A (es)
EP (2) EP1114644B1 (es)
JP (1) JP4187075B2 (es)
AR (1) AR009066A1 (es)
AT (2) ATE205722T1 (es)
AU (1) AU731745B2 (es)
CA (1) CA2261799C (es)
DE (2) DE69706872T2 (es)
DK (2) DK1114644T3 (es)
ES (2) ES2162321T3 (es)
HK (1) HK1042229B (es)
IL (1) IL128128A (es)
PT (2) PT1114644E (es)
SI (1) SI1114644T1 (es)
WO (1) WO1998006423A1 (es)
ZA (1) ZA976598B (es)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
US7312196B2 (en) * 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US6410511B2 (en) * 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
WO1998032458A1 (en) * 1997-01-23 1998-07-30 Sumitomo Pharmaceuticals Company, Limited Remedies for diabetes
EP1006794B1 (en) * 1997-03-12 2007-11-28 Robert W. Esmond A method for treating or preventing alzheimer's disease
AU766219B2 (en) * 1998-02-02 2003-10-09 1149336 Ontario Inc. Method of regulating glucose metabolism, and reagents related thereto
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
ATE367828T1 (de) * 1998-04-03 2007-08-15 Novartis Vaccines & Diagnostic Igf-enthaltende injizierbare formulierungen enthaltend succinate als puffermittel
US6436897B2 (en) 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
US6211144B1 (en) * 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
JP4360758B2 (ja) * 1999-04-08 2009-11-11 ジェネンテック・インコーポレーテッド 逆の電荷のポリペプチド類をベースにした組成物
WO2001000223A2 (en) * 1999-06-25 2001-01-04 Minimed Inc. Multiple agent diabetes therapy
ES2569916T3 (es) 1999-06-29 2016-05-13 Mannkind Corporation Formulaciones farmacéuticas que comprenden insulina complejada con una dicetopiperazina
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US7582311B1 (en) 1999-10-15 2009-09-01 Genentech, Inc. Injection vehicle for polymer-based formulations
US7651703B2 (en) * 1999-10-15 2010-01-26 Genentech, Inc. Injection vehicle for polymer-based formulations
AU2002248464A1 (en) 2001-02-21 2002-09-12 Medtronic Minimed, Inc. Stabilized insulin formulations
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
SE0101982D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
SE0101980D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
FR2826278B1 (fr) * 2001-06-20 2005-03-25 Lipha Utilisation d'agents antidiabetiques pour fabriquer un medicament ayant un effet cicatrisant
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
EP1469873A4 (en) * 2001-11-26 2007-10-03 Tufts College PEPTIDOMIMETIC INHIBITORS FROM BEHIND PROLIN SPLENDING ENZYMES
WO2003045228A2 (en) * 2001-11-26 2003-06-05 Trustees Of Tufts College Methods for treating autoimmune disorders, and reagents related thereto
US10022078B2 (en) 2004-07-13 2018-07-17 Dexcom, Inc. Analyte sensor
US6923175B2 (en) 2002-03-20 2005-08-02 Mannkind Corporation Inhalation apparatus
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
EP2460530A3 (en) 2002-12-31 2012-08-29 Althea Technologies, Inc. Human growth hormone crystals and methods for preparing them
EA200501422A1 (ru) * 2003-03-04 2006-04-28 Дзе Текнолоджи Девелопмент Компани Лтд. Длительнодействующая инъецируемая композиция инсулина и способы её изготовления и применения
GB0308732D0 (en) * 2003-04-15 2003-05-21 Axcess Ltd Absorption enhancers
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
US20080090753A1 (en) * 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
DE602005014962D1 (de) * 2004-03-12 2009-07-30 Biodel Inc Insulinzusammensetzungen mit verbesserter wirkstoffabsorption
US20080096800A1 (en) * 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
US8989833B2 (en) 2004-07-13 2015-03-24 Dexcom, Inc. Transcutaneous analyte sensor
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
KR20130066695A (ko) 2004-08-23 2013-06-20 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
US8133178B2 (en) 2006-02-22 2012-03-13 Dexcom, Inc. Analyte sensor
JP2008542235A (ja) * 2005-05-25 2008-11-27 ノボ・ノルデイスク・エー／エス 安定化ポリペプチド製剤
US8097584B2 (en) * 2005-05-25 2012-01-17 Novo Nordisk A/S Stabilized formulations of insulin that comprise ethylenediamine
MX373000B (es) 2005-09-14 2020-05-21 Mannkind Corp Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
WO2007041481A1 (en) * 2005-09-29 2007-04-12 Biodel, Inc. Rapid acting and prolonged acting insulin preparations
US7713929B2 (en) 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
EP1986679B1 (en) 2006-02-22 2017-10-25 MannKind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
WO2007121256A2 (en) 2006-04-12 2007-10-25 Biodel, Inc. Rapid acting and long acting insulin combination formulations
US20090147006A1 (en) * 2007-12-07 2009-06-11 Roche Diagnostics Operations, Inc. Method and system for event based data comparison
FR2925333B1 (fr) * 2007-12-19 2012-04-13 Farid Bennis Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives
US20090175840A1 (en) * 2008-01-04 2009-07-09 Biodel, Inc. Insulin formulations for insulin release as a function of tissue glucose levels
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
CN101827626B (zh) 2008-06-13 2015-03-18 曼金德公司 干粉吸入器和用于药物输送的系统
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
ES2421385T3 (es) 2008-06-20 2013-09-02 Mannkind Corp Aparato interactivo y procedimiento para establecer el perfil, en tiempo real, de esfuerzos de inhalación
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
CN102256618A (zh) 2008-10-17 2011-11-23 赛诺菲-安万特德国有限公司 胰岛素和glp-1激动剂的组合
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
WO2010089706A1 (en) 2009-02-04 2010-08-12 Ecole Polytechnique Federale De Lausanne (Epfl) Use of igf-1 and nt-3 in the treatment of x-linked adrenoleukodystrophy
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
DK2405963T3 (da) 2009-03-11 2013-12-16 Mannkind Corp Apparat, system og fremgangsmåde til at måle modstand i en inhalator
KR102584844B1 (ko) 2009-06-12 2023-10-04 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
PL2451437T3 (pl) 2009-07-06 2017-05-31 Sanofi-Aventis Deutschland Gmbh Wodne preparaty insuliny zawierające metioninę
US9357951B2 (en) 2009-09-30 2016-06-07 Dexcom, Inc. Transcutaneous analyte sensor
CA2778698A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
NZ599847A (en) 2009-11-13 2013-09-27 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
TR201809460T4 (tr) 2009-11-13 2018-07-23 Sanofi Aventis Deutschland Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim.
CN102985125A (zh) 2010-06-21 2013-03-20 曼金德公司 干粉药物输送系统和方法
WO2012028172A1 (en) 2010-08-30 2012-03-08 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
SG194034A1 (en) 2011-04-01 2013-11-29 Mannkind Corp Blister package for pharmaceutical cartridges
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
US9993529B2 (en) 2011-06-17 2018-06-12 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
AR087693A1 (es) 2011-08-29 2014-04-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
MX2014004983A (es) 2011-10-24 2014-09-22 Mannkid Corp Metodos y composiciones para tratar dolor.
KR102264177B1 (ko) 2012-07-12 2021-06-11 맨카인드 코포레이션 건조 분말 약물 전달 시스템 및 방법
AR091902A1 (es) * 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
JP2016505601A (ja) * 2012-12-26 2016-02-25 ウォックハート リミテッド 医薬組成物
EP3587404B1 (en) 2013-03-15 2022-07-13 MannKind Corporation Microcrystalline diketopiperazine compositions, methods for preparation and use thereof
MX375448B (es) 2013-07-18 2025-03-06 Mannkind Corp Composiciones farmacéuticas en polvo seco estables al calor y métodos.
EP3030294B1 (en) 2013-08-05 2020-10-07 MannKind Corporation Insufflation apparatus
JP6723921B2 (ja) * 2014-01-09 2020-07-15 サノフイＳａｎｏｆｉ インスリンアナログおよび／またはインスリン誘導体の、グリセリンを含まない安定化された医薬製剤
CN105960249B (zh) 2014-01-09 2021-03-16 赛诺菲 胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
PE20171622A1 (es) 2014-12-12 2017-11-02 Sanofi Aventis Deutschland Formulacion de relacion fija de insulina glargina/lixisenatida
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
EP4228676B1 (en) * 2020-10-19 2025-01-08 Oak Hill Bio Limited Compositions suitable for use in neonates
DE102021122096A1 (de) * 2021-08-26 2023-03-02 Forschungsinstitut für Nutztierbiologie IGF-1, IGFBP-2 und Insulin umfassende Zusammensetzungen und ihre Verwendung

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3486491T2 (de) * 1983-04-25 2003-01-16 Chiron Corp., Emeryville Hybrid-DNS-Synthesis von reifen insulinähnlichen Wachstumsfaktoren
IL71991A (en) * 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
US5091173A (en) * 1989-06-29 1992-02-25 The University Of Dundee Hair growth composition
GB8920381D0 (en) * 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
JPH0818999B2 (ja) * 1990-01-05 1996-02-28 藤沢薬品工業株式会社 インシュリン様成長因子ｉの乾燥製剤
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5656590A (en) * 1991-05-24 1997-08-12 Amylin Pharmaceuticals, Inc. Treatment of anorexia and related states
US5202119A (en) * 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response
JPH0543453A (ja) * 1991-08-20 1993-02-23 Sumitomo Pharmaceut Co Ltd 創傷治癒促進用局所用徐放性製剤
HUT67319A (en) * 1991-08-30 1995-03-28 Life Medical Sciences Inc Compositions for treating wounds
AU673659B2 (en) * 1991-11-25 1996-11-21 Institute Of Molecular Biology, Inc. Medicament for promoting growth of mammalian nerve
DE4208552A1 (de) * 1992-03-17 1993-09-23 Liedtke Pharmed Gmbh Topische arzneiformen mit insulin
SE9201573D0 (sv) * 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1
JPH07501082A (ja) * 1992-06-24 1995-02-02 ホット　ペッパー　ワックス　インコーポレーテッド 有機殺虫剤
JPH08500827A (ja) * 1992-08-26 1996-01-30 セルトリックス ファーマシューティカルズ，インコーポレイテッド 異化症状および全身性組織創傷の全身的治療方法
WO1994016722A1 (en) * 1993-01-25 1994-08-04 The Beth Israel Hospital Association Method for modifying, diagnosing, and screening for igf-i sensitive cell barrier properties
CA2154078A1 (en) * 1993-01-29 1994-08-04 George N. Cox Wound healing composition
SE9402119D0 (sv) * 1994-06-16 1994-06-16 Pharmacia Ab Solution
SE9402331D0 (sv) * 1994-07-01 1994-07-01 Pharmacia Ab New use
SE9402370D0 (sv) * 1994-07-04 1994-07-04 Pharmacia Ab Use of IGF-I
AUPM678294A0 (en) * 1994-07-13 1994-08-04 Gropep Pty Ltd Use of insulin-like growth factor in combination with insulin
ATE410182T1 (de) * 1998-01-09 2008-10-15 Amylin Pharmaceuticals Inc Formulierungen für amylin peptidagonisten mit insulin
ES2177323T3 (es) * 1998-10-16 2002-12-01 Novo Nordisk As Preparaciones de insulina concentradas estables para la administracionpor via pulmonar.
JP4360758B2 (ja) * 1999-04-08 2009-11-11 ジェネンテック・インコーポレーテッド 逆の電荷のポリペプチド類をベースにした組成物
WO2001000223A2 (en) * 1999-06-25 2001-01-04 Minimed Inc. Multiple agent diabetes therapy

Also Published As

Publication number Publication date
EP0918536B1 (en) 2001-09-19
DE69706872D1 (de) 2001-10-25
HK1042229B (en) 2003-08-15
JP4187075B2 (ja) 2008-11-26
AU731745B2 (en) 2001-04-05
ZA976598B (en) 1999-02-17
PT1114644E (pt) 2002-12-31
EP1114644B1 (en) 2002-08-14
DE69714796T2 (de) 2003-04-03
JP2000516229A (ja) 2000-12-05
DE69714796D1 (de) 2002-09-19
WO1998006423A1 (en) 1998-02-19
PT918536E (pt) 2002-03-28
ATE222120T1 (de) 2002-08-15
AR009066A1 (es) 2000-03-08
CA2261799C (en) 2009-09-08
IL128128A0 (en) 1999-11-30
ES2162321T3 (es) 2001-12-16
DK1114644T3 (da) 2002-11-04
DE69706872T2 (de) 2002-04-25
CA2261799A1 (en) 1998-02-19
HK1042229A1 (en) 2002-08-09
SI1114644T1 (en) 2002-12-31
US5783556A (en) 1998-07-21
EP1114644A1 (en) 2001-07-11
DK0918536T3 (da) 2001-12-03
AU3824397A (en) 1998-03-06
ATE205722T1 (de) 2001-10-15
EP0918536A1 (en) 1999-06-02
IL128128A (en) 2007-06-17

Similar Documents

Publication Publication Date Title
ES2180523T3 (es) Composicion que comprende insulina nph (insulina neutra protamina de hagedorn).
ZA981130B (en) Compositions containing hydroxy acids or retinoids.
AU7956894A (en) Metal-binding targeted polypeptide constructs
EP1302848A3 (en) A microprocessor having a multiply operation
AU7528894A (en) Hydrazino-type n2s2 chelators
ZA944283B (en) Gps-aided dead reckoning navigation
AU4298596A (en) Protracted glp-1 compositions
AU1094892A (en) Improved activation of recombinant proteins
AU1378395A (en) Metal chelators
FI853220A7 (fi) Aminoalkoksibentsopyranonit antipsykoottisina ja anksiolyyttisinä aineina.
AU6281994A (en) Novel androgens and anabolic agents
DK0394787T3 (da) Midler indeholdende carbonamidgruppeholdige (meth)acrylsyreestere til anvendelse som klæbestofkomponenter til behandling af kollagenholdige materialer i medicinen, samt fremstillingen af disse midler
DE69720335D1 (de) Recombinante Fructosyl-Aminosäure-Oxidase
WO1995015391A3 (en) Aspergillus expression system
FI854678A7 (fi) Motordriven truck.
EP0806821A3 (en) Polirazed superfluorescent fiber sources
EP0630963A3 (en) Acid micro-emulsion.
ATE294189T1 (de) Kristallisation von proteinen
AU7028798A (en) Use of 2-methylthiazolidine-2,4-dicarboxylic acid as mucolytic agent
AU1477295A (en) Use of azoles as virucidal agents in solutions of biologically active proteins
FI931887A7 (fi) Nestemäisiä koostumuksia, jotka sisältävät karboksyyliestereitä
AU560165B2 (en) Chromophoric peptides
BRPI9612617B8 (pt) vetor recombinante, microorganismo hospedeiro geneticamente modificado, método para determinar a presença de compostos genotóxicos em uma amostra e método para determinar tanto a genotoxicidde quanto a mutagenicidade de uma amostra
DE68920580D1 (de) Anzeigesystem mit direktem Farbmodus.
GB9604518D0 (en) Novel compounds